A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Jul 2017
At a glance
- Drugs PF 5251749 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 24 Jul 2017 Status changed to completed.
- 20 Jun 2017 Planned End Date changed from 19 May 2017 to 12 Aug 2017.
- 20 Jun 2017 Planned primary completion date changed from 19 May 2017 to 12 Aug 2017.